News

Sulfatinib is an oral, novel angio-immunokinase inhibitor that selectively targets vascular endothelial growth factor receptor (“VEGFR”), fibroblast growth factor receptor (“FGFR”) and colony-stimulating factor-1 receptor (“CSF-1R”), three key

Founded in 2016, Wren was spun out of the University of Cambridge and Lund University, Sweden. It is engaged in the drug discovery and development for protein misfolding diseases,

The SMC approved the use of Elbasvir-grazoprevir, known as Zepatier, saying it is a combination of two medicines that inhibit the replication of the Hepatitis C virus and

The Company intends to complete a reduction in force affecting 25 employees, including Jon Congleton, President and Chief Executive Officer, and David Rodman, M.D., Chief Medical Officer and

Baricitinib is being co-developed by Eli Lilly and Company and Incyte under an exclusive global license and collaboration agreement signed in December 2009. It is intended to be taken orally

The improvement was observed in the 4mg/day dose arm, while the 2mg/day dose arm did not show a statistically significant difference from placebo. Both dasotraline arms were generally

Aprepitant belongs to a class of agents known as NK1 receptor antagonists, which are often used in combination with 5-HT3 receptor antagonists for the prevention of CINV. The

The new capital will be used primarily to develop a novel clinical stage asset targeting the CD24-Siglec pathway that regulates host inflammatory response to tissue injuries, which has

The QIDP status provides for accelerated review of the New Drug Application (NDA) as well as a five-year period of market exclusivity for the indication, if approved. Currently,